Nomenclature for Kidney Function and Disease: Executive Summary and Glossary From a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference

Abstract

A primary obligation of medical journals is the responsible, professional, and expeditious delivery of knowledge from researchers and practitioners to the wider community.1Levey A.S. Weiner D.E. editorial teamStaying put, but not standing still.Am J Kidney Dis. 2012; 59: 1-3Abstract Full Text Full Text PDF PubMed Scopus (20) Google Scholar The task of journal editors, therefore, rests not merely in selecting what to publish, but in large measure judging how it can best be communicated. The challenge of improving descriptions of kidney function and disease in medical publishing was the impetus for a KDIGO (Kidney Disease: Improving Global Outcomes) Consensus Conference held in June 2019. The conference goals included standardizing and refining kidney-related nomenclature used in English-language scientific articles and developing a glossary that can be used by journals.2Kidney Disease: International Global OutcomesConsensus Conference on Nomenclature for Kidney Function & Disease.https://kdigo.org/conferences/nomenclature/Date accessed: April 24, 2020Google Scholar The rationale for the conference was that the worldwide burden of kidney disease is rising, but public awareness remains limited, underscoring the need for effective communication by stakeholders in the kidney health community.3Plantinga L.C. Boulware L.E. Coresh J. et al.Patient awareness of chronic kidney disease: trends and predictors.Arch Intern Med. 2008; 168: 2268-2275Crossref PubMed Scopus (203) Google Scholar, 4James S.L. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.Lancet. 2018; 392: 1789-1858Abstract Full Text Full Text PDF PubMed Scopus (2762) Google Scholar, 5GBD Chronic Kidney Disease CollaborationGlobal, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.Lancet. 2020; 395: 709-733Abstract Full Text Full Text PDF PubMed Scopus (471) Google Scholar, 6Saran R. Robinson B. Abbott K.C. et al.US Renal Data System 2017 annual data report: epidemiology of kidney disease in the United States.Am J Kidney Dis. 2018; 71: S1-S676PubMed Google Scholar Despite this need, the nomenclature for describing kidney function and disease lacks uniformity and clarity. Two decades ago, a survey of hundreds of published articles and meeting abstracts reported a broad array of overlapping, confusing terms for chronic kidney disease (CKD) and advocated adoption of unambiguous terminology.7Hsu C.Y. Chertow G.M. Chronic renal confusion: insufficiency, failure, dysfunction, or disease.Am J Kidney Dis. 2000; 36: 415-418Abstract Full Text Full Text PDF PubMed Scopus (104) Google Scholar Nevertheless, terms flagged by that analysis as problematic, such as “chronic renal failure” and “pre-dialysis,” still appear in current-day publications. A coherent, shared nomenclature could improve communication at all levels, to not only foster better appreciation of the burden of disease but also aid understanding of how patients feel about their disease, allow more effective communication between kidney disease specialists and other clinicians, advance more straightforward comparison and integration of datasets, enable better recognition of gaps in knowledge for future research, and facilitate more comprehensive public health policies for acute and chronic kidney disease. Developing consistent, patient-centered, and precise descriptions of kidney function and disease in the scientific literature is an important objective to align communication in clinical practice, research, and public health. Although some terms have been in use for decades, the increased exchange of information among stakeholders makes it timely to revisit nomenclature in order to ensure consistency. The goal is to facilitate communication within and across disciplines and between practitioners and patients, with the ultimate hope of improving outcomes through consistency and precision. Attendees at the conference included editors of kidney subspecialty journals, kidney subspecialty editors at general medical journals and journals from other subspecialties, experienced authors of clinical kidney health research, and patients. Guiding principles of the conference were that the revised nomenclature should be patient-centered, precise, and consistent with nomenclature used in the KDIGO guidelines. The discussion focused on general description of acute and chronic kidney disease and kidney measures, rather than specific kidney diseases and particular measures of function and structure. Classifications of causes of kidney disease and procedures, performance measures, and outcome metrics for dialysis and transplantation were considered beyond the scope of discussion. As described in detail in the conference report,8Levey A.S. Eckardt K.-U. Dorman N.M. et al.Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference [e-pub ahead of print].Kidney Int. 2020; 97: 1117-1129Abstract Full Text Full Text PDF PubMed Scopus (100) Google Scholar the meeting attendees reached general consensus on the following recommendations: (i) to use “kidney” rather than “renal” or “nephro-” when referring to kidney disease and kidney function; (ii) to use “kidney failure” with appropriate descriptions of presence or absence of symptoms, signs, and treatment rather than “end-stage kidney disease”; (iii) to use the KDIGO definition and classification of acute kidney diseases and disorders (AKD) and acute kidney injury (AKI) rather than alternative descriptions to define and classify the severity of these; (iv) to use the KDIGO definition and classification of CKD rather than alternative descriptions to define and classify it; and (v) to use specific kidney measures, such as albuminuria or decreased glomerular filtration rate, rather than “abnormal” or “reduced” kidney function to describe alterations in kidney structure and function (Box 1). Accordingly, the proposed glossary contains 5 corresponding sections, and comprises specific items for which there was general agreement among the conference participants (Table S1).8Levey A.S. Eckardt K.-U. Dorman N.M. et al.Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference [e-pub ahead of print].Kidney Int. 2020; 97: 1117-1129Abstract Full Text Full Text PDF PubMed Scopus (100) Google Scholar For each section, the glossary includes preferred terms, abbreviations, descriptions, and terms to avoid, with the acknowledgment that journals may choose which of the recommendations to implement, and that journal style will dictate when and how to abbreviate terms to be consistent with nomenclature for other diseases.Box 1Key takeaways from the conferenceTabled 1• Use the term “kidney” rather than “renal” to describe kidney function and kidney disease. In English, the terms renal and kidney are still used interchangeably, resulting in different acronyms describing the same condition or status (e.g., ESRD/ESKD and RRT/KRT). It is more likely that patients and the public would understand the terms incorporating the more familiar noun “kidney,” rather than the less familiar adjective “renal,” which is derived from Latin and is labeled as technical in some dictionaries. Although writing guides may generally favor using an appropriate adjective over a noun as a modifier, there are high-profile precedents for the use of kidney as a modifier, such as AKI, CKD, and NIDDK (National Institute of Diabetes and Digestive and Kidney Diseases).• Avoid the term “end-stage.” Although rooted in US law, the term is not patient sensitive, may connote a stigma, and may discourage advocacy. In the US, ESRD (ESKD) is a synonym for receipt of KRT. However, KRT is a treatment rather than a disease. The term “kidney failure,” which is defined as GFR <15 ml/min per 1.73 m2 or treatment by dialysis, is as comprehensive as “ESRD/ESKD,” without suffering from its limitations.• Improve characterization of the full spectrum of kidney failure. Although all patients with kidney failure have GFR <15 ml/min per 1.73 m2 or are undergoing treatment by dialysis, the severity of symptoms varies greatly. We lack terms to describe the severity of symptoms and signs, and yet they are indications for initiating KRT. There are also no common patient-reported outcome measures to describe severity. The term “kidney failure” in a chronic setting is defined as >3 months, whereas in an acute setting (i.e., AKI stage 3), it is reserved for a duration of ≤3 months. Kidney failure could be further classified according to patient-reported outcomes (symptoms).• Use more-descriptive terms for treatments for kidney failure. Many patients with kidney failure do not undergo KRT. The terms “treated” vs. “untreated” have been used, but this is not consistent with the idea that supportive care is indeed treatment. Furthermore, in some cases, patients choose supportive care rather than KRT; in other cases, they do not have a choice because of lack of insurance or lack of availability. Finally, some patients may not be under the care of a physician at all.• Avoid the use of “chronic kidney disease (CKD)” as a synonym for “GFR <60 ml/min per 1.73 m2.” CKD includes markers of kidney damage or GFR <60 ml/min per 1.73 m2 for >3 months, so ascertainment of GFR without assessment for markers of kidney damage is insufficient for classification of CKD status when GFR > 60 ml/min per 1.73 m2. If chronicity is not documented, it can be inferred on the basis of corroborative clinical data or presumed in the absence of clinical data to the contrary.• Avoid the use of “acute kidney injury (AKI)” as a synonym for “acute kidney diseases and disorders (AKD).” AKD refers to kidney diseases and disorders with a duration of ≤3 months, whereas AKI refers to kidney diseases and disorders with onset within 1 week.• Use “CKD GFR and albuminuria categories” and “AKI stages” to describe disease severity, rather than employing ill-defined terms such as “mild,” “moderate,” “severe,” and “advanced.”• Use the terms “GFR categories” and “albuminuria categories” rather than “CKD stages” when describing the level of GFR and albuminuria in populations either without CKD or without ascertainment of both GFR and albuminuria.• Use the term “risk categories” to describe combinations of the G (GFR) and A (albuminuria) categories from the KDIGO heat map (see Supplementary Figure S1).• Use specific terms, such as “GFR,” “tubular secretion,” “tubular reabsorption,” “albuminuria,” and “proteinuria,” rather than general terms, such as “abnormal” or “reduced” kidney function, damage, or injury, when possible. Because kidney function comprises several functional categories, including excretory, endocrine, and metabolic functions, it should be described as specifically as possible. GFR is closely linked with the excretory function, but it should not be used as a synonym, because tubular reabsorption and excretion also contribute to excretory function.• When referring to “decreased or decreasing GFR,” avoid the use of different, poorly defined terms such as “impaired kidney function,” “renal insufficiency,” “renal dysfunction,” “renal impairment,” “worsening kidney function,” and “kidney function decline.”• When referring to GFR, use descriptive abbreviations (mGFR for measured GFR and eGFR for estimated GFR, with specific notation based on the endogenous filtration markers used (e.g., eGFRcr, eGFRcys, and eGFRcr-cys). Additional detail can be given in the methods. For mGFR, the methods should describe the exogenous filtration marker (e.g., inulin, iothalamate, iohexol) and clearance method (urinary clearance, plasma clearance). For eGFR, the methods should describe the estimating equation used (CKD-EPI; MDRD Study).• Avoid referring to “albuminuria” or “proteinuria” as “decreased kidney function.” Albuminuria and proteinuria are markers of kidney damage, rather than measures of kidney function.• When referring to albuminuria or proteinuria, avoid the terms “microalbuminuria” and “macroalbuminuria/clinical proteinuria.” Use the terms “moderately increased” or “severely increased” instead.• When referring to albuminuria and proteinuria, use descriptive abbreviations, such as “urine albumin or protein excretion rates (AER and PER)” and “urine albumin–creatinine or protein–creatinine ratios (ACR and PCR).”ACR, albumin-creatinine ratio; AER, albumin excretion rate; AKD, acute kidney diseases and disorders; AKI, acute kidney injury; CKD, chronic kidney disease; CKD-EPI, CKD Epidemiology Collaboration; eGFR, estimated glomerular filtration rate; eGFRcr, estimated glomerular filtration rate derived from creatinine; eGFRcr-cys, estimated glomerular filtration rate derived from creatinine and cystatin C; eGFRcys, estimated glomerular filtration rate derived from cystatin C; ESKD, end-stage kidney disease; ESRD, end-stage renal disease; GFR, glomerular filtration rate; KDIGO, Kidney Disease: Improving Global Outcomes; KRT, kidney replacement therapy; MDRD, Modification of Diet in Renal Disease; mGFR, measured glomerular filtration rate; NIDDK, National Institute of Diabetes and Digestive and Kidney Diseases; PCR, protein-creatinine ratio; PER, protein excretion rate; RRT, renal replacement therapy; US, United States. Open table in a new tab Tabled 1• Use the term “kidney” rather than “renal” to describe kidney function and kidney disease. In English, the terms renal and kidney are still used interchangeably, resulting in different acronyms describing the same condition or status (e.g., ESRD/ESKD and RRT/KRT). It is more likely that patients and the public would understand the terms incorporating the more familiar noun “kidney,” rather than the less familiar adjective “renal,” which is derived from Latin and is labeled as technical in some dictionaries. Although writing guides may generally favor using an appropriate adjective over a noun as a modifier, there are high-profile precedents for the use of kidney as a modifier, such as AKI, CKD, and NIDDK (National Institute of Diabetes and Digestive and Kidney Diseases).• Avoid the term “end-stage.” Although rooted in US law, the term is not patient sensitive, may connote a stigma, and may discourage advocacy. In the US, ESRD (ESKD) is a synonym for receipt of KRT. However, KRT is a treatment rather than a disease. The term “kidney failure,” which is defined as GFR <15 ml/min per 1.73 m2 or treatment by dialysis, is as comprehensive as “ESRD/ESKD,” without suffering from its limitations.• Improve characterization of the full spectrum of kidney failure. Although all patients with kidney failure have GFR <15 ml/min per 1.73 m2 or are undergoing treatment by dialysis, the severity of symptoms varies greatly. We lack terms to describe the severity of symptoms and signs, and yet they are indications for initiating KRT. There are also no common patient-reported outcome measures to describe severity. The term “kidney failure” in a chronic setting is defined as >3 months, whereas in an acute setting (i.e., AKI stage 3), it is reserved for a duration of ≤3 months. Kidney failure could be further classified according to patient-reported outcomes (symptoms).• Use more-descriptive terms for treatments for kidney failure. Many patients with kidney failure do not undergo KRT. The terms “treated” vs. “untreated” have been used, but this is not consistent with the idea that supportive care is indeed treatment. Furthermore, in some cases, patients choose supportive care rather than KRT; in other cases, they do not have a choice because of lack of insurance or lack of availability. Finally, some patients may not be under the care of a physician at all.• Avoid the use of “chronic kidney disease (CKD)” as a synonym for “GFR <60 ml/min per 1.73 m2.” CKD includes markers of kidney damage or GFR <60 ml/min per 1.73 m2 for >3 months, so ascertainment of GFR without assessment for markers of kidney damage is insufficient for classification of CKD status when GFR > 60 ml/min per 1.73 m2. If chronicity is not documented, it can be inferred on the basis of corroborative clinical data or presumed in the absence of clinical data to the contrary.• Avoid the use of “acute kidney injury (AKI)” as a synonym for “acute kidney diseases and disorders (AKD).” AKD refers to kidney diseases and disorders with a duration of ≤3 months, whereas AKI refers to kidney diseases and disorders with onset within 1 week.• Use “CKD GFR and albuminuria categories” and “AKI stages” to describe disease severity, rather than employing ill-defined terms such as “mild,” “moderate,” “severe,” and “advanced.”• Use the terms “GFR categories” and “albuminuria categories” rather than “CKD stages” when describing the level of GFR and albuminuria in populations either without CKD or without ascertainment of both GFR and albuminuria.• Use the term “risk categories” to describe combinations of the G (GFR) and A (albuminuria) categories from the KDIGO heat map (see Supplementary Figure S1).• Use specific terms, such as “GFR,” “tubular secretion,” “tubular reabsorption,” “albuminuria,” and “proteinuria,” rather than general terms, such as “abnormal” or “reduced” kidney function, damage, or injury, when possible. Because kidney function comprises several functional categories, including excretory, endocrine, and metabolic functions, it should be described as specifically as possible. GFR is closely linked with the excretory function, but it should not be used as a synonym, because tubular reabsorption and excretion also contribute to excretory function.• When referring to “decreased or decreasing GFR,” avoid the use of different, poorly defined terms such as “impaired kidney function,” “renal insufficiency,” “renal dysfunction,” “renal impairment,” “worsening kidney function,” and “kidney function decline.”• When referring to GFR, use descriptive abbreviations (mGFR for measured GFR and eGFR for estimated GFR, with specific notation based on the endogenous filtration markers used (e.g., eGFRcr, eGFRcys, and eGFRcr-cys). Additional detail can be given in the methods. For mGFR, the methods should describe the exogenous filtration marker (e.g., inulin, iothalamate, iohexol) and clearance method (urinary clearance, plasma clearance). For eGFR, the methods should describe the estimating equation used (CKD-EPI; MDRD Study).• Avoid referring to “albuminuria” or “proteinuria” as “decreased kidney function.” Albuminuria and proteinuria are markers of kidney damage, rather than measures of kidney function.• When referring to albuminuria or proteinuria, avoid the terms “microalbuminuria” and “macroalbuminuria/clinical proteinuria.” Use the terms “moderately increased” or “severely increased” instead.• When referring to albuminuria and proteinuria, use descriptive abbreviations, such as “urine albumin or protein excretion rates (AER and PER)” and “urine albumin–creatinine or protein–creatinine ratios (ACR and PCR).”ACR, albumin-creatinine ratio; AER, albumin excretion rate; AKD, acute kidney diseases and disorders; AKI, acute kidney injury; CKD, chronic kidney disease; CKD-EPI, CKD Epidemiology Collaboration; eGFR, estimated glomerular filtration rate; eGFRcr, estimated glomerular filtration rate derived from creatinine; eGFRcr-cys, estimated glomerular filtration rate derived from creatinine and cystatin C; eGFRcys, estimated glomerular filtration rate derived from cystatin C; ESKD, end-stage kidney disease; ESRD, end-stage renal disease; GFR, glomerular filtration rate; KDIGO, Kidney Disease: Improving Global Outcomes; KRT, kidney replacement therapy; MDRD, Modification of Diet in Renal Disease; mGFR, measured glomerular filtration rate; NIDDK, National Institute of Diabetes and Digestive and Kidney Diseases; PCR, protein-creatinine ratio; PER, protein excretion rate; RRT, renal replacement therapy; US, United States. Open table in a new tab ACR, albumin-creatinine ratio; AER, albumin excretion rate; AKD, acute kidney diseases and disorders; AKI, acute kidney injury; CKD, chronic kidney disease; CKD-EPI, CKD Epidemiology Collaboration; eGFR, estimated glomerular filtration rate; eGFRcr, estimated glomerular filtration rate derived from creatinine; eGFRcr-cys, estimated glomerular filtration rate derived from creatinine and cystatin C; eGFRcys, estimated glomerular filtration rate derived from cystatin C; ESKD, end-stage kidney disease; ESRD, end-stage renal disease; GFR, glomerular filtration rate; KDIGO, Kidney Disease: Improving Global Outcomes; KRT, kidney replacement therapy; MDRD, Modification of Diet in Renal Disease; mGFR, measured glomerular filtration rate; NIDDK, National Institute of Diabetes and Digestive and Kidney Diseases; PCR, protein-creatinine ratio; PER, protein excretion rate; RRT, renal replacement therapy; US, United States. A guiding principle for the development of the glossary was patient-centeredness. The and of the US National of care as care that is and patient and and that patient all clinical on the of in the United States. Institute of the A System for the National Scholar of the general principles for of the health is shared and information should have to their medical information and to clinical and patients should and In the terms used to describe kidney function and disease should be to with acknowledgment of in the level of health Use of terms with can to as can use of terms that the future as rather than describe the However, of an of terms that of the glossary are to that that have been and that may be more familiar or should be of Scholar to in the development of the glossary was which can generally be defined as or of Scholar is defined and is from a in which may be to a that will more precise of clinical The in which a is to the clinical and and treatment in In the Kidney by the National of to and kidney from participants with AKI or a kidney define disease and and for Scholar As in it is that that in more precise disease descriptions will be nomenclature for kidney function and disease, rather than it the glossary is to be consistent with knowledge and to for the it is also to be to new with in the A of the proposed glossary is that it is based on KDIGO and nomenclature for acute and chronic kidney disease. In it was using the a systematic including of a and rationale and of patient Eckardt et and on terms used to describe kidney health [e-pub ahead of J Scholar and a corresponding a of public on conference and of consensus among attendees at the Although the recommendations are not likely to all the consensus among conference attendees was that standardizing scientific nomenclature is a to improving among clinicians, and public health and with patients, their and and the of the proposed glossary are that it is to may be to only a of stakeholders were to to it is not comprehensive not disease dialysis, and further is for in For and other the recommendations for a glossary to be an important and it will future and consensus among conference and of the conference report and is only the in of a revised The glossary in will be on the KDIGO of the glossary will be included in to the of the of et of A for and Scholar journals the recommendations will need to how to and this will of editorial as as communication with generally and with to specific If further in clinical practice, research, and public health will more and Improving communication with patients and the public will to improve patient and health for the and guides to communication with patients. and patient will be to in research, in will a of new terms and disease and In the and of patient and in and best in clinical care will further the of and the KDIGO glossary can be as of the of future KDIGO and and The conference was by KDIGO and in by from and from National Institute of Diabetes and Digestive and Kidney and National Kidney from and from and and from and from & from and Renal from and Renal from and from and from and from and from National of The authors that they have no The authors are to at for with The of this not the or of the journal at the for the information and is to the editorial was for in Kidney by the as a it not undergo editorial or at Kidney is published in Kidney International and in several The articles and but in and and of in with each of may be used in this are with of KDIGO and the International of with Supplementary

Topics & Concepts